PD-1/PD-L1免疫检查点抑制剂致心脏毒性的研究进展
Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
-
摘要: 心脏毒性是抗肿瘤药物的严重不良反应，随着抗肿瘤药物的不断发展，免疫检查点抑制剂已被应用于多种癌症的治疗，特别是程序性死亡受体1（PD-1）或程序性死亡配体1（PD-L1）免疫检查点抑制剂近年来受到广泛关注，本文将从PD-1及PD-1/PD-L1免疫检查点抑制剂概述、PD-1/PD-L1免疫检查点抑制剂致心脏毒性的表现及可能机制的探索、心脏毒性的检测方法和PD-1/PD-L1所致心脏毒性的治疗等方面进行综述。Abstract: Cardiotoxicity is a serious complication of antineoplastic drugs. With the continuous development of antineoplastic drugs, immune checkpoint inhibitors have been used in the treatment of a variety of cancers. PD-1/PD-L1 immune checkpoint inhibitors have been widely concerned in recent years. This article reviews the manifestations and possible mechanisms of cardiotoxicity induced by PD-1/PD-L1 immune checkpoint inhibitors, and the detection methods and treatment of cardiotoxicity.
下载:
